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Abstract
Background: Some patients may have normal wall motion after myocardial infarction. The aim of this study was
to determine the prevalence and prognosis of patients with myocardial scar in the absence of abnormal wall
motion. We studied patients with suspected or known coronary artery disease (CAD) who were referred for
cardiovascular magnetic resonance (CMR) for the assessment of global and regional cardiac function and late
gadolinium enhancement (LGE) and had normal left ventricular wall motion. Prognostic value was determined by
the occurrence of hard endpoints (cardiac death and nonfatal myocardial infarction) and major adverse cardiac
events (MACE) which also included hospitalization due to unstable angina or heart failure or life threatening
ventricular arrhythmia.
Results: A total 1148 patients (70.3%) were studied. LGE was detected in 104 patients (9.1%). Prevalence of LGE
increased in patients with increased left ventricular mass. Average follow-up time was 955 ± 542 days. LGE was the
strongest predictor for hard endpoints and MACE.
Conclusion: LGE was detected in 9.1% of patients with suspected or known CAD and normal wall motion. LGE
was the strongest predictor of significant cardiac events.
Background
Assessment of structural heart disease or ventricular
function has been recommended for patients presenting
with signs or symptoms of heart disease such as dyspnea
on exertion, heart failure [1], chest pain or angina [2],
and acute coronary syndrome [3]. Structural heart dis-
ease such as valvular heart disease and global or regional
ventricular function is usually evaluated by echocardio-
graphy [1-3]. Left ventricular ejection fraction (LVEF) is
one of the most important indices of global left ventri-
cular function and wall motion abnormality represents
regional myocardial function. The prevalence of myocar-
dial infarction by clinical history may be underestimated
since approximately 20-40% of myocardial infarction
may be unrecognized [4,5]. The prognostic importance
of late gadolinium enhancement (LGE) has been
reported in many groups of patients such as coronary
artery disease (CAD) [6], non-ischemic cardiomyopathy
[7] and diabetic patients [8]. It has been shown that the
presence [6,8] and size [8] of myocardial scar and the
presence of abnormal wall motion [8] had an impact on
the prognosis of patients without clinical history of
myocardial infarction. Little is known about the preva-
lence and prognosis of myocardial scar in patients with
known or suspected CAD and normal wall motion.
Cardiovascular magnetic resonance (CMR) is consid-
ered the gold standard for the assessment of global ven-
tricular function [9,10] and a good tool for the
assessment of regional ventricular function [11]. It also
provides the data concerning myocardial scar, most com-
monly related to myocardial infarction, by LGE techni-
que. This technique has been proven to be very accurate,
comparable to histopathology [12], and have better accu-
racy than single photon emission computed tomography
[12,13], even in the setting of very small infarction [14],
and it has also been shown to be highly reproducible [15].
The objectives of this study were 1) to determine pre-
valence of myocardial scar in patients with known or
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and 2) to determine the prognostic value of myocardial
scar in patients with known or suspected CAD in the
absence of abnormal wall motion.
Methods
Study population
We studied patients who were referred for CMR from
January 2002 to December 2007. Patients were referred
for CMR due to clinical symptoms suspected to be
related to CAD. Patients were included in this study if 1)
known or suspected CAD who was referred for CMR for
the evaluation of myocardial function and LGE 2) age
more than 30 years and 3) normal left ventricular wall
motion from CMR. Types of symptoms are shown in
T a b l e1 .P a t i e n t sw e r ee x c l u d e di fa n yo ft h ef o l l o w i n g
criteria is presence: 1) had contraindication for CMR
such as pacemaker or internal defibrillator implantation
2) history of myocardial infarction documented by stan-
dard criteria [16] 3) poor quality images for myocardial
function or LGE 4) inability to complete CMR examina-
tion 5) history of revascularization 6) known disease that
could cause LGE such as dilated cardiomyopathy [17],
hypertrophic cardiomyopathy [18], myocarditis [19], car-
diac amyloidosis [20] 7) clinically unstable conditions 8)
need for urgent revascularization and 9) data unobtain-
able on clinical-follow-up. Since we excluded patients
with history of myocardial infarction and history of revas-
cularization, known CAD was defined as a history of at
least 50% diameter stenosis of one or more major coron-
ary arteries from coronary angiography who did not
undergo revascularization and those with history of myo-
cardial ischemia by nuclear study.
This study was approved by the Ethics committee of
Siriraj Hospital. All patients provided written informed
consent.
CMR protocol
All patients underwent CMR which included functional
study and assessment of LGE using a 1.5 Tesla Gyroscan
NT Philips scanner (Philip Medical System, Best, the
Netherlands). After scout images, functional study was
performed with a steady-state free-precession technique
in horizontal long axis view, 2-chamber view, 4-chamber
view and multiple slice short axis view. LGE was per-
formed in 3-D fashion 7-10 minute after the injection of
gadolinium 0.2 mmol/kg. Multiple short-axis slices at
the same level as the functional study, 2-chamber and
4-chamber view were acquired for LGE.
Parameters for functional images were as follows:
repetition time/echo time/number of excitations = 3.7/
1.8/2, 390 × 312 mm field of view, 256 × 240 matrix,
1.52 × 1.21 reconstruction pixel, 8 mm slice thickness,
70 degree flip angle. Typical temporal resolution was
25-30 ms. The LGE images were acquired with the use
of 3 D segmented-gradient-echo inversion-recovery
sequence with echo time 1.25, repetition time 4.1, 15
degree flip angle, 303 × 384 mm field of view, 240 ×
256 matrix, in-plane resolution 1.26 × 1.5 mm, slice
thickness 8 mm and 1.5 Sensitivity encoding factor. The
whole study for each patient took approximately 40
minutes. Patients had ECG performed on the same day
before undergoing CMR. Myocardial infarction by ECG
was defined by the standard criteria [16].
Analysis of CMR
The analysis was performed on the ViewForum worksta-
tion (Philip Medical System, Best, the Netherlands). Func-
tional CMR data were analyzed for volume, mass and
ejection fraction of the left ventricle. The software made
an automatic detection of the endocardial and epicardial
border of the left ventricle during diastole and endocardial
detection for images during systole. Manual adjustment
Table 1 Baseline characteristics of patients with and
without LGE. Values are numbers (percentages) unless
otherwise stated.
Characteristics All
N = 1148
LGE
N = 104
No LGE
N = 1044
P
Value
Male 481 (41.9) 66 (63.5) 415 (39.8) <0.001
Mean (SD)
age (years)
64.6 (11.3) 64.9 (12.5) 64.6 (11.2) 0.817
Smoking 148 (12.9) 19 (18.3) 129 (12.4) 0.086
Hypercholesterolemia 729 (63.5) 77 (74) 652 (62.5) 0.019
Diabetes mellitus 381 (33.2) 40 (38.5) 341 (32.7) 0.231
Hypertension 732 (63.8) 76 (73.1) 656 (62.8) 0.038
History of dyspnea on
exertion
477 (41.6) 53 (51) 424 (40.6) 0.041
History of heart failure 23 (2) 2 (1.9) 21 (2) 0.951
Presence of chest pain 576 (50.2) 48 (46.2) 528 (50.6) 0.390
Medication
-Beta blockers 487 (42.4) 48 (46.2) 439 (42) 0.419
-Calcium channel
blockers
288 (25.1) 21 (20.2) 267 (25.6) 0.227
-Nitrates 284 (24.7) 27 (26) 257 (24.6) 0.762
-Aspirin/clopidogrel 600 (52.3) 60 (57.7) 540 (51.7) 0.245
-ACEI/ARB 334 (29.1) 40 (38.5) 294 (28.2) 0.027
-Statins 541 (47.1) 59 (56.7) 482 (46.2) 0.040
MI by ECG 89 (7.8) 17 (18.1) 72 (7.4) <0.001
CMR variables in mean
(SD)
-LVEF (%) 71.0 (9.1) 69.8 (10.7) 71.1 (9.0) 0.255
-LVEDVI (ml/m
2) 60.6 (19.6) 62.4 (22.0) 60.4 (19.4) 0.320
-LVESVI (ml/m
2) 18.6 (14.1) 20.5 (17.7) 18.4 (13.7) 0.258
-LVMASSI (g/m
2) 48.8 (17.3) 63.0 (31.7) 47.3 (14.5) <0.001
LGE = late gadolinium enhancement, MI = myocardial infarction, CMR =
cardiovascular magnetic resonance, ACEI = angiotensin converting enzyme
inhibitors, ARB = angiotensin receptor blockers, LVEF = left ventricular ejection
fraction, LVEDVI = left ventricular end-diastolic volume index, LVESVI = left
ventricular end-systolic volume index, LVMASSI = left ventricular mass index
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then made calculations for left ventricular end-diastolic
volume (LVEDV), left ventricular end-systolic volume
(LVESV), left ventricular mass (LVMASS), and LVEF. Cal-
culation of indices of LVEDV (LVEDVI), LVESV (LVESVI)
and LVMASS (LVMASSI) was performed to adjust for
body surface area. Intra- and interobserver variability pre-
sented as percentages of the mean of 2 repeated measure-
ments averaged ± standard deviations were 3 ± 4% and 4
± 4% for LVEDV, 4 ± 5% and 6 ± 6% for LVESV and 3 ±
4% and 5 ± 5% for LVMASS.
LGE was analyzed by visual estimation for the pre-
sence or absence of LGE and quantification of LGE.
LGE was graded segmental extent of LGE as follows:
0 = no scar, 1 = 1-25%, 2 = 26-50%, 3 = 51-75%, and
4 = 76-100% of LGE areas in comparison to segmental
myocardial areas. Analysis of myocardial segments was
b a s e do n1 7 - s e g m e n tm o d e l s[ 21] with the exclusion of
segment 17 from analysis. Slices was classified as basal
segments when tips of mitral valve is visualized, mid-
cavity segments when papillary muscles are visualized
and apical segments when they are beyond papillary
muscles but before the cavity ends [21]. Each of the
basal and mid-cavity slices was divided into 6 segments
and each of the apical slices was divided into 4 seg-
ments. Total scar size was derived from the summation
of scar grading of all segments, divided by 4 times the
total myocardial segments and calculated as percentages
of scar in comparison with myocardium [12].
Analysis of wall motion was performed by visual assess-
ment. Wall motion and LGE was assessed by 2 readers
independently of the history. Disagreement was solved by
a3
rd reader. Regional wall motion was analyzed by the use
of the 17-segment model proposed by the American Heart
Association [21]. Wall motion of each myocardial segment
was recorded as 5-grade system as followed: 1 = normal,
2 = hypokinesia, 3 = akinesia, or 4 = dyskinesia. Intra- and
interobserver agreement for the presence of a LGE area in
our center were k = 0.94, p <0.001 and k = 0.97, p <0.001
respectively using a signal intensity threshold of more than
2 standard deviations above the signal intensity of a
remote myocardial region. The cut off of 2 standard devia-
tions has been used in many previous studies [6-8]. Visual
detection for LGE has been shown to be in a good agree-
ment with the conventional technique with k = 0.952, p <
0.001 [22]. For the presence of abnormal wall motion,
intra- and interobserver agreement were k = 0.95, p
<0.001 and k = 0.93, p <0.001 respectively
Clinical follow-up
Primary outcomes include both hard cardiac events and
major adverse cardiac events (MACE). Cardiac death and
myocardial infarction were considered as hard cardiac
events. MACE includes hard cardiac events and
hospitalization due to unstable angina, heart failure or life-
threatening ventricular arrhythmia. Assessment of cardiac
events was performed by the review of medical records and
telephone interview followed by document confirmation.
Statistical analysis
Data were described as mean ± standard deviation (SD)
for continuous data and count (percentages) for catego-
rical data. Independent-samples T-test was used for the
comparison of continuous data. Comparisons of catego-
r i c a ld a t aw e r em a d eb yt h eC h i - s q u a r et e s to rF i s h e r
exact test wherever appropriate. Cox-regression analysis
was used for the assessment of predictors for clinical
outcomes and was described as hazard ratio and 95%
confidence interval (CI). Kaplan-Meier analysis with log-
rank test was used for survival analysis with comparison
of survival data between groups. A p-value of ≤ 0.05 was
considered significant.
Results
We excluded 248 patients with a history of revasculariza-
tion, 252 patients with a history of myocardial infarction,
18 patients who were unable to complete CMR examina-
tion, 8 patients with inadequate image quality, 4 patients
with pacemakers, 5 patients with unstable clinical condi-
tions, 14 patients unobtainable clinical follow-up data, 10
patients with mid-wall or patchy scar likely to be non-
ischemia cardiomyopathy scar, 3 patients with scar at the
insertion site of right ventricular free-wall likely to be
related to hypertrophic cardiomyopathy, 2 patients with
subepicardial scar likely to be related to myocarditis, and 1
patient with diffuse LGE likely to be related to amyloido-
sis. After the exclusion, total of 1148 patients with normal
left ventricular wall motion were included in this study.
Average age was 64.6 ± 11.3 years. LGE was detected in
104 patients (9.1%). Table 1 shows baseline characteristics
of patients with and without LGE. The following factors
were associated with LGE: male gender, hypercholesterole-
mia, hypertension, a history of dyspnea on exertion, use of
certain medications such as angiotensin converting
enzyme inhibitor (ACEI) or angiotensin receptor blocker
(ARB), and statin. There were 132 patients (11.5%) who
underwent coronary angiogram before CMR study. The
results of coronary angiogram showed single vessel disease
in 35 (27%), 2-vessel disease in 32 (24%), 3-vessel disease
in 29 (22%) and no significant CAD in 36 patients (27%).
Comparisons of CMR functional parameters were per-
formed (Table 1). There was no significant difference in
LVEF between patients with and without LGE. LVMASS
index was significantly greater in patients with LGE in
comparison to those without LGE. We further explored
the relation between increased LVMASS index and the
presence of LGE by dividing LVMASS index into 4
quartile groups. The prevalence of LGE was only 2.8%
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valence increased to 5.2%, 9.1% and 19.2% in the 2
nd,3
rd
and highest quartile respectively (Figure 1).
Coronary angiography data after CMR of those who
had LGE was explored to confirm the underlying CAD
in this group. Among 104 patients with LGE, 48 (46.2%)
underwent coronary angiography, 12 had single vessel
disease, 15 had 2-vessel disease, 20 had 3-vessel disease,
and only 1 patient had no significant CAD. Among
those who underwent coronary angiography, 24 were in
the highest quartile of LVMASS index, 13 in the 3
rd
quartile, 4 in the 2
nd quartile and 7 in the lowest quar-
tile. Figure 2 shows example of a patient with increased
LVMASS index (3
rd quartile group) had LGE without
abnormal wall motion. Among patients without LGE,
coronary angiogram was performed in 145 patients
(13.9%) which demonstrated single vessel disease in 39,
2-vessel disease in 30, 3-vessel disease in 30, and no sig-
nificant CAD in 46 patients.
Predictors for cardiac events
During an average follow-up time of 955 ± 542 days, 18
patients (1.6%) had hard cardiac events and 54 (4.7%)
had MACE. The frequency of cardiac events is shown in
Table 2. Univariate predictors and multivariable analysis
for hard cardiac events and MACE were analyzed (Table 3
and 4). LGE is the only significant predictor for MACE
and strongest predictor for hard cardiac event followed by
myocardial infarction by ECG. However, as in Table 1
chance of having ECG evidence of myocardial infarction
was small in patients with LGE. Besides, myocardial infarc-
tion diagnosed by ECG had a significant chance of false
positive as it was noted in 7.4% of patients without LGE.
Overall sensitivity, specificity, positive predictive value and
negative predictive value of ECG evidence of myocardial
infarction for the detection of LGE were 18.1%, 92.6%,
19.1%, and 92.1% respectively. Kaplan-Meier graph with
log rank test of LGE as the predictor for hard cardiac
events and MACE is shown in Figure 3. Since there may
be a possibility that some patients may undergo coronary
angiography or revascularization related to the results of
CMR and had cardiac events caused by the procedures,
we looked at the rate of cardiac events related to the pro-
cedures in both groups within 6 months after the CMR.
Revascularization was performed in 28 patients (26.9%)
who had LGE and 79 patients who had no LGE (7.6%).
Figure 1 Percentages of LGE stratified by quartiles of LVMASS index.
Figure 2 Functional images at diastole (A), systole (B) and LGE images (C) of a patient with LGE at inferior wall (black arrow), normal
wall motion and increased left ventricular mass index.
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revascularization within 6 months after CMR: 1 in LGE
group (0.96%) and 4 in non-LGE group (0.38%) which had
no statistical significance (p = 0.379).
Additional analysis was performed for the assessment of
the prognostic importance of the extent of LGE. By using
the median size of LGE of 6.25% of myocardium, we graded
the extent of LGE into 3 groups: no LGE, LGE ≤ median
and LGE > median. Hazard ratios and 95%CI for hard car-
diac events and MACE for patients with LGE ≤ median
were 2.14 (0.28-16.53), p = 0.467 and 3.36 (1.32-8.55), p =
0.011 compared to those without LGE. Multivariable analysis
showed that patients with LGE ≤ median had no significant
increase in risk of hard events but had a significant increase
in risk of MACE (hazard ratio 3.28, 95%CI 1.29-8.37, p =
0.013) compared to those without LGE. For patients with
LGE > median, hazard ratios for hard events and MACE
were 8.59 (3.23-24.37), p < 0.001 and 4.69 (2.28-9.67), p <
0.001 compared to those without LGE. Multivariable analysis
showed that patients with LGE > median had a significant
increase in risk of hard events (hazard ratio 7.96, 95%CI
2.34-27.09, p = 0.001) and MACE (hazard ratio 4.51, 95%CI
2.19-9.30, p < 0.001) compared to those without LGE.
Discussion
The results of our study showed that in patients with
known or suspected CAD and normal wall motion, 9.1%
Table 2 Summary of clinical events during follow-up.
Values are numbers (percentages).
Clinical events Number (%)
Total death 32 (2.8)
Cardiac death 5 (0.4)
Myocardial infarction 13 (1.1)
Hospitalization due to heart failure 21 (1.8)
Hospitalization due to unstable angina 26 (2.3)
Life-threatening ventricular arrhythmia 1 (0.1)
Coronary angiogram 172 (15)
-no significant coronary artery disease 48 (27.9)
-significant coronary artery disease 124 (72.1)
-single vessel disease 44 (35.5)
-double vessel disease 38 (30.7)
-triple vessel disease 42 (33.8)
Percutaneous coronary intervention 77 (6.7)
Coronary bypass surgery 30 (2.6)
Table 3 Univariate predictors of hard endpoints and MACE
Clinical characteristics Cardiac Death or Nonfatal MI (N = 18-1.6%) P Value MACE
(N = 54 - 4.7%)
P Value
Male 1.42 (0.56-23.57) 0.460 1.13 (0.66-1.93) 0.655
Body mass index > 25 kg/m
2 0.25 (0.08-0.77) 0.016 0.72 (0.42-1.22) 0.220
Age (per 10 year increment) 0.94 (0.63-1.40) 0.756 1.15 (0.90-1.48) 0.256
Smoking 0.48 (0.06-3.61) 0.475 0.67 (0.24-1.85) 0.437
Hypercholesterolemia 0.95 (0.37-2.44) 0.909 1.22 (0.69-2.15) 0.487
Diabetes mellitus 1.058 (0.62-4.00) 0.335 2.01 (1.18-3.42) 0.010
Hypertension 0.73 (0.29-1.86) 0.514 1.10 (0.63-1.93) 0.730
Prior chest pain 0.30 (0.10-0.90) 0.032 0.84 (0.49-1.44) 0.523
Prior dyspnea 0.95 (0.37-2.46) 0.922 0.82 (0.47-1.43) 0.473
Prior heart failure 1.58 (0.56-5.85) 0.235 2.18 (0.53-8.96) 0.279
Medication
-Beta blockers 0.38 (0.13-1.17) 0.092 0.93 (0.54-1.61) 0.805
-Calcium antagonist 0.19 (0.42-3.34) 0.742 1.20 (0.66-2.17) 0.556
-Nitrates 0.90 (0.30-2.72) 0.845 1.01 (0.54-1.88) 0.986
-Aspirin/clopidogrel 0.60 (0.23-1.52) 0.274 1.02 (0.60-1.73) 0.954
-ACEI/ARB 0.70 (0.23-2.13) 0.531 0.87 (0.47-1.5) 0.644
-Statins 0.60 (0.22-1.59) 0.301 0.71 (0.41-1.23) 0.216
MI by ECG 7.02 (2.20-22.38) 0.001 1.65 (0.59-4.60) 0.340
CMR variables
-presence of LGE 5.74 (2.15-15.33) <0.001 4.12 (2.23-7.57) <0.001
-LVEF (per 10% decrement) 1.39 (0.90-2.14) 0.135 1.19 (0.91-1.56) 0.208
-LVEDVI 1.007 (1.000-1.014) 0.041 1.006 (1.000-1.011) 0.038
-LVESVI 1.012 (1.001-1.024) 0.040 1.009 (1.000-1.019) 0.054
-LVMASS index (per quartile) 2.57 (1.36-6.45) <0.001 2.11 (1.27-5.56) <0.001
MI = myocardial infarction, MACE = major adverse cardiac event, ACEI = angiotensin converting enzyme inhibitors, ARB = angiotensin receptor blockers, CMR =
cardiovascular magnetic resonance, LGE = late gadolinium enhancement, LVEF = left ventricular ejection fraction, LVEDVI = left ventricular end-diastolic volume
index, LVESVI = left ventricular end-systolic volume index, LVMASSI = left ventricular mass index
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cardiovascular events compared to those without.
In fact, LGE is the strongest predictor of cardiac events.
Echocardiography is an investigation for the evaluation
of evidence of structural heart disease in patients with
sign or symptoms of heart disease [1-3]. CMR, although
of limited availability and more expensive, can assess
evidence of structural heart disease to a greater extent
than echocardiography [17,18,20]. Although echocardio-
graphy may have a better temporal resolution than
CMR, the overall image quality of CMR for the assess-
ment of regional wall motion is usually better than
echocardiography (11, 23). In comparison with echocar-
diography, CMR has a better tissue contrast and better
border definition thereby better endocardial detection.
Image quality of echocardiography may also be compro-
mised due to a poor acquisition window. CMR has been
shown to be very accurate for the detection of myocar-
dial scar [12] which may be related to a better image
quality of CMR in comparison to echocardiography [9].
A previous study [5] showed that patients with unrecog-
nized myocardial infarction diagnosed from ECG had
regional wall motion abnormality, from echocardiogram,
in 13% compared to 42% in those with recognized
myocardial infarction. This may be due to the limited
accuracy of ECG criteria for the diagnosis of myocardial
infarction [4].
We showed that, among patients with normal wall
motion, the prevalence of LGE increased in patients with
high LVMASS index with the prevalence up to 19% in
the highest quartile of LVMASS index. This finding is
consistent with a previous report [5] which showed an
increased LVMASS index from echocardiogram in
patients with unrecognized myocardial infarction.
Compared to earlier report [6] on the prognostic
importance of LGE in patients with known or suspected
CAD, we focused on patients with normal wall motion
which has not been reported before. We also had a lar-
g e rn u m b e ro fp a t i e n t sw i t hn o r m a lw a l lm o t i o n .
Although they reported the findings of LGE and abnor-
mal wall motion, the number of patients with normal
wall motion in their study was small and cannot provide
the prognostic data in this group. Calculation from the
data that they reported, the prevalence of LGE in
patients with normal wall motion was 7% which is
slightly less than the prevalence in our study.
The results of this study on the prevalence of LGE
and its prognostic value can be applied to patients who
were referred for CMR with normal left ventricular wall
motion without known cause of LGE. This is the reason
that we excluded patients with history of myocardial
infarction and other known causes of LGE including
those with history of revascularization which may have a
significant number of procedure-related LGE which was
detected by CMR in up to 64% [14].
There are some limitations of this study. Firstly,
although we exclude hypertrophic cardiomyopathy and
many conditions that might cause LGE, we did not
exclude left ventricular hypertrophy or aortic stenosis
Table 4 Multivariable associations for hard endpoints
and MACE
HR (95% CI) P Value
Cardiac death or nonfatal MI
-LGE 5.43 (1.71-17.25) 0.004
-MI by ECG 5.14 (1.62-16.29) 0.005
MACE
-LGE 3.92 (1.98-7.76) <0.001
MACE = major adverse cardiac event, HR = hazard ratio, CI = confidence
interval, MI = myocardial infarction, LGE = late gadolinium enhancement
Figure 3 Kaplan-Meier graph of LGE and occurrence of hard cardiac events (left) and MACE (right).
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[ 2 4 ] .H o w e v e r ,i nt h i ss t u d y ,w ed i dn o th a v ea n y
patients with severe aortic stenosis and LGE was an
independent predictor after the adjustment of LVMASS.
Secondly, the detection of abnormal wall motion was
performed by visual assessment without the use of
quantitative analysis although intra- and inter-observer
agreements for wall motion assessment in our study
were excellent as shown earlier. Lastly, this study did
not analyze the influence of inducible wall motion
abnormality or perfusion abnormality that might also
have an effect on clinical outcome due to inadequate
number of patients.
Conclusion
This is the first study that demonstrated the prognostic
importance of LGE in patients with normal wall motion.
The prognostic value of LGE in this patient population
was even more confirmed by the quantitative analysis of
LGE. Therefore, clinicians cannot assume that patients
without wall motion abnormality have no evidence of
structural heart disease and have a good prognosis.
Although myocardial infarction by ECG was also an
independent predictor for hard endpoints, LGE was the
strongest predictor of hard endpoints and MACE.
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